Actively Recruiting
Evaluation of Safety and Effects of MER511 by Intravenous and Subcutaneous Administration in Adults with Graves Disease
Led by Merida Biosciences · Updated on 2026-10-29
100
Participants Needed
17
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate how well MER511 is tolerated and what side effects it may cause in adults aged 18 to 65 with Graves disease. It is a Phase 1, first-in-human, multicenter study that assesses safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending doses of MER511 administered intravenously or subcutaneously. The study has two parts. Part A tests single ascending doses of MER511 given intravenously or subcutaneously compared to placebo. Part B evaluates multiple ascending subcutaneous doses of MER511 or placebo given on Day 1 and Day 29. Participants are assigned to cohorts receiving different dose levels in a randomized, double-blind design. Participants will undergo blood tests to study how MER511 behaves in the body and its effects. Researchers will monitor treatment-emergent adverse events, vital signs, ECGs, lab values, and physical exams up to 16 weeks in Part A and 24 weeks in Part B. The study also measures drug concentration levels and immune response. Total participation lasts through these monitoring periods to assess safety and drug activity.
CONDITIONS
Brief Title
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
Research Team
C
Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here